Profound Medical Corp. (PROF)
| Market Cap | 515.50M |
| Revenue (ttm) | 4.22M |
| Net Income (ttm) | -15.41M |
| Shares Out | 11.85M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $26.37 |
| Previous Close | $25.38 |
| Change ($) | 0.99 |
| Change (%) | 3.90% |
| Day's Open | 25.47 |
| Day's Range | 24.91 - 26.80 |
| Day's Volume | 118,374 |
| 52-Week Range | 6.88 - 26.80 |
I have put an emphasis on value in 2021; however, I am not sitting still in my aggressive portfolio. I have added 2 new positions and added to a third. All 3 companies look to benefit from a r...
TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incisio...
TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which ...
TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administr...
TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which ...
Profound Medical has unique differentiators via their TULSA-PRO procedure that provide a breakthrough in an otherwise complex treatment domain. The company has faced headwinds from COVID-19 th...
TORONTO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which ...
Profound Medical Corp. (PROF) CEO Arun Menawat on Q3 2020 Results - Earnings Call Transcript
TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which ...
TORONTO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which ...
TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies w...
TORONTO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies wh...
Profound Medical Corp. (PROF) CEO Arun Menawat on Q2 2020 Results - Earnings Call Transcript
PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -43.48% and -1.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies wh...
TORONTO, July 22, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies wh...
TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced und...
TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering ...
TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it intends to file a preliminary prospectu...
Profound Medical (PROF) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
TULSA-PRO, the most flexible prostate treatment on the market.
TORONTO, May 20, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special ...
PROFOUND MEDICL (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TORONTO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, inc...
Profound Medical: Non-Surgical Prostatectomy Is Profound
TORONTO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, inc...
About PROF
Profound Medical operates as a medical technology company develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases, as well as non-invasive treatment of uterine fibroids. Pro... [Read more...]
| Industry Medical Devices | |
| CEO Dr. Arun Swarup Menawat | Employees 75 |
| Stock Exchange NASDAQ | Ticker Symbol PROF |
Financial Performance
In 2019, PROF's revenue was 5.53 million, an increase of 112.41% compared to the previous year's 2.60 million. Losses were -20.19 million, -2.75% less than in 2018.